On this page
- BILLION GROUP HOLDINGS Ltd IPO
- Bonus Biogroup Ltd. IPO
- Fenbo Holdings Ltd IPO
- Linkers Industries Ltd IPO
- Medical 21, Inc. IPO
- MiniMed Group, Inc. IPO
- Papa Medical Inc. IPO
- Sharewow Ltd IPO
BILLION GROUP HOLDINGS Ltd IPO
BILLION GROUP HOLDINGS Ltd filed a Form F-1 registration statement for an initial public offering on 2025-08-29. It has amended it 6 times. As of its latest filing, on 2026-03-03, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We will apply to have our Ordinary Shares listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “BGHL”.From the F-1 filed 2026-03-03
This is the initial public offering of 3,750,000 Ordinary Shares (as defined below) of Billion Group Holdings Limited, a Cayman Islands exempted company.From the F-1 filed 2026-03-03
We currently intend to use the net proceeds from this offering to (i) expand our market reach and strengthen our sales and distribution infrastructure (approximately 45%), (ii) enhance our brand awareness and invest in marketing and advertising initiatives (approximately 35%), and (iii) for general corporate purposes (approximately 20%).From the F-1 filed 2026-03-03
Pursuant to Rule 477 under the Securities Act, the Company hereby requests that the Commission consent to the withdrawal of the Registration Statement, effective as of the date hereof.From the RW filed 2026-02-27
| Filed | What it is | Filing |
|---|---|---|
| 2025-08-29 | Registration statement filed (foreign issuer) | F-1 |
| 2025-09-11 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-09-12 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-09-22 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-09-25 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-10-01 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-10-28 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-02-27 | Request to withdraw a registration (Form F-1) | RW |
| 2026-03-03 | Registration statement filed (foreign issuer) | F-1 |
Bonus Biogroup Ltd. IPO
Bonus Biogroup Ltd. filed a Form F-1 registration statement for an initial public offering on 2025-05-09. It has amended it 4 times. As of its latest filing, on 2026-03-31, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We have applied to list the ADSs on the Nasdaq Capital Market, or Nasdaq, under the symbol “BONS.” This offering is contingent upon the listing of the ADSs on Nasdaq.From the F-1/A filed 2026-03-31
We are offering 3,750,000 American Depositary Shares, or ADSs, through the underwriter named in this prospectus.From the F-1/A filed 2026-03-31
The estimated initial public offering price is between $4.00 and $6.00 per ADS.From the F-1/A filed 2026-03-31
We currently intend to use the net proceeds from this offering, together with our existing cash resources, as follows:From the F-1/A filed 2026-03-31
Since the date of the Private Placement Agreement, and as of December 31, 2025, we have incurred net losses of NIS 362.1 million (equivalent to approximately $113.5 million).From the F-1/A filed 2026-03-31
| Filed | What it is | Filing |
|---|---|---|
| 2025-05-09 | Registration statement filed (foreign issuer) | F-1 |
| 2025-11-28 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-03-12 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-03-19 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-03-31 | Registration statement amended (foreign issuer) | F-1/A |
Fenbo Holdings Ltd IPO
Fenbo Holdings Ltd filed a Form F-1 registration statement for an initial public offering on 2024-07-26. It has amended it 4 times. As of its latest filing, on 2026-03-26, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
Our Class A Ordinary Shares are listed on the Nasdaq Capital Market under the symbol “FEBO”.From the F-1 filed 2026-03-26
We are offering, on a reasonable best-efforts basis, up to US$10,000,000 Units (the “Units”).From the F-1 filed 2026-03-26
We currently intend to use the net proceeds, if any, from this offering as follows:From the F-1 filed 2026-03-26
Our net loss from operations for the for the six months ended June 30, 2025 and 2024 was HK$3,826,000 (US$487,000) and HK$1,901,000, respectively.From the F-1 filed 2026-03-26
Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), the Company hereby requests that the Commission consent to the withdrawal of the Registration Statement effective as of the date hereof or at the earliest practicable date hereafter and requests that a written order granting the withdrawal of the Registration Statement and all exhibits and amendments thereto be issued by the Commission as soon as reasonably practicable.From the RW filed 2025-01-06
| Filed | What it is | Filing |
|---|---|---|
| 2024-07-26 | Registration statement filed (foreign issuer) | F-1 |
| 2024-08-14 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-08-20 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-08-23 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-08-29 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-01-06 | Request to withdraw a registration (Form F-1) | RW |
| 2026-03-26 | Registration statement filed (foreign issuer) | F-1 |
Linkers Industries Ltd IPO
Linkers Industries Ltd filed a Form F-1 registration statement for an initial public offering on 2026-03-16. It has amended it 3 times. It filed its final prospectus on 2026-03-24, at a public offering price of $0.69 per share. Each fact below is quoted from the filing named with it.
Our Class A Ordinary Shares are listed on Nasdaq under the symbol “LNKS”.From the 424B4 filed 2026-03-24
We are offering 1,900,000 Class A Ordinary Shares of LIL, representing 14.45 % of the issued and outstanding ordinary shares, par value US$0.00001 per shares (“Ordinary Shares”), of LIL following completion of this offering, assuming the underwriters do not exercise their over -allotment option.From the 424B4 filed 2024-12-05
We estimate that the net proceeds to us from this offering will be approximately $14,386,900, at the public offering price of $0.693 per Ordinary Unit, after deducting the Placement Agent’s fees, accountable expense allowance and estimated offering expenses payable by us.From the 424B4 filed 2026-03-24
We plan to use the net proceeds of this offering as follows:From the 424B4 filed 2024-12-05
The sales of wire/cable harnesses in Malaysia grew at a CAGR of 5.7% between 2017 and 2022, with revenue increased from US$509.5 million in 2017 to US$672.3 million in 2022.From the F-1/A filed 2024-08-19
| Filed | What it is | Filing |
|---|---|---|
| 2024-08-09 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-08-19 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-09-23 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-12-05 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-03-16 | Registration statement filed (foreign issuer) | F-1 |
| 2026-03-24 | Final prospectus filed: the offering is priced | 424B4 |
Medical 21, Inc. IPO
Medical 21, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-02-19. It has amended it 2 times. As of its latest filing, on 2026-03-20, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 23, 2026 | Form D, private offering | $550K sold | Form D page | Source |
We intend to use the net proceeds from this offering for to complete a first -in-human clinical trial and begin an expanded feasibility study, continue animal studies, conduct regulatory activities, further develop our product, and for working capital and other general corporate purposes.From the S-1/A filed 2026-03-20
For the year ended December 31, 2025, net cash used in operating activities was $3,761,214 primarily due to our net loss of $10,238,759 and changes in our operating assets and liabilities of $235,829, which was partially offset by non -cash expenses of $6,713,873.From the S-1/A filed 2026-03-20
MiniMed Group, Inc. IPO
MiniMed Group, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-12-19. It has amended it 3 times. It filed its final prospectus on 2026-03-06, at a public offering price of $20.00 per share. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 16, 2026 | Leadership change: Amy Bricker appointed, Director | — | Leadership changes | Source |
| August 5, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| June 29, 2026 | Leadership change: David Endicott appointed, Director, and 1 more | — | Leadership changes | Source |
| May 18, 2026 | Leadership change: Brett Wall departs, Director, and 1 more | — | Leadership changes | Source |
Our common stock has been approved for listing on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “MMED.”From the 424B4 filed 2026-03-06
This is an initial public offering of shares of the common stock of MiniMed Group, Inc. We are offering 28,000,000 shares of our common stock.From the 424B4 filed 2026-03-06
The initial public offering price per share of our common stock is $20.00 per share.From the 424B4 filed 2026-03-06
In the six months ended October 24, 2025, we achieved Net Loss of $21 million and Adjusted EBITDA of $128 million.From the S-1/A filed 2026-02-27
Papa Medical Inc. IPO
Papa Medical Inc. filed a Form S-1 registration statement for an initial public offering on 2024-11-22. It has amended it 4 times. As of its latest filing, on 2026-03-20, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We intend to apply to have our Class A common stock listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “PAPA.” The offering is contingent upon final approval of our Nasdaq listing, and we will not complete the offering if our Class A common stock is not listed on Nasdaq.From the S-1/A filed 2026-03-20
This is the initial public offering of 3,750,000 shares of Class A common stock on a firm commitment basis.From the S-1/A filed 2026-03-20
We plan to use the net proceeds of this offering as follows, assuming no exercise of the underwriters’ over -allotment option:From the S-1/A filed 2026-03-20
| Filed | What it is | Filing |
|---|---|---|
| 2024-11-22 | Registration statement filed | S-1 |
| 2025-06-27 | Registration statement amended | S-1/A |
| 2025-07-14 | Registration statement amended | S-1/A |
| 2025-08-07 | Registration statement amended | S-1/A |
| 2025-11-26 | Registration statement filed | S-1 |
| 2025-12-15 | Request to withdraw a registration (Form S-1) | RW |
| 2025-12-15 | Request to withdraw a registration (Form S-1) | RW |
| 2026-03-20 | Registration statement amended | S-1/A |
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.